ZA941239B - Excipient stabilazation of polypeptides treated with organic solvents - Google Patents

Excipient stabilazation of polypeptides treated with organic solvents

Info

Publication number
ZA941239B
ZA941239B ZA941239A ZA941239A ZA941239B ZA 941239 B ZA941239 B ZA 941239B ZA 941239 A ZA941239 A ZA 941239A ZA 941239 A ZA941239 A ZA 941239A ZA 941239 B ZA941239 B ZA 941239B
Authority
ZA
South Africa
Prior art keywords
pct
organic solvents
excipient
stabilazation
polypeptides treated
Prior art date
Application number
ZA941239A
Other languages
English (en)
Inventor
Jeffrey L Cleland
Andrew J S Jones
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA941239B publication Critical patent/ZA941239B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA941239A 1993-02-23 1994-02-23 Excipient stabilazation of polypeptides treated with organic solvents ZA941239B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2142193A 1993-02-23 1993-02-23

Publications (1)

Publication Number Publication Date
ZA941239B true ZA941239B (en) 1995-08-23

Family

ID=21804127

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA941239A ZA941239B (en) 1993-02-23 1994-02-23 Excipient stabilazation of polypeptides treated with organic solvents

Country Status (17)

Country Link
US (3) US5589167A (fr)
EP (1) EP0686045B1 (fr)
JP (1) JP3698721B2 (fr)
CN (1) CN1108823C (fr)
AT (1) ATE197550T1 (fr)
AU (1) AU685784B2 (fr)
CZ (1) CZ296649B6 (fr)
DE (1) DE69426292T2 (fr)
DK (1) DK0686045T3 (fr)
ES (1) ES2153418T3 (fr)
GR (1) GR3035383T3 (fr)
IL (1) IL108713A (fr)
NZ (1) NZ262634A (fr)
PT (1) PT686045E (fr)
RU (1) RU2143889C1 (fr)
WO (1) WO1994019020A1 (fr)
ZA (1) ZA941239B (fr)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
EP0782398A1 (fr) 1994-09-22 1997-07-09 Quadrant Holdings Cambridge Limited Compositions de rehydratation et de nutrition a utiliser pendant une activite sportive, et leurs procedes de preparation
US6964771B1 (en) * 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
SI2275119T1 (sl) * 1995-07-27 2013-12-31 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
DE69717263T2 (de) 1996-03-28 2003-07-24 Takeda Chemical Industries, Ltd. Zubereitung mit verzögerter freisetzung und deren herstellung
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
CA2259403A1 (fr) * 1996-07-03 1998-01-08 Alza Corporation Formulations protiques non aqueuses de peptides
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US6468782B1 (en) * 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
KR20000057693A (ko) 1996-12-20 2000-09-25 다케다 야쿠힌 고교 가부시키가이샤 지효성 제제의 제조 방법
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
IL134084A0 (en) 1997-07-18 2001-04-30 Infimed Inc Biodegradable macromers for the controlled release of biologically active substances
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
AU2945199A (en) * 1998-03-18 1999-10-11 Ronai, Peter Amorphous glasses for stabilising sensitive products
DK1069912T3 (da) * 1998-04-03 2007-11-12 Novartis Vaccines & Diagnostic Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel
CN1379681A (zh) * 1998-04-17 2002-11-13 安乔格尼克斯公司 治疗性的血管生成因子及其使用方法
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6190701B1 (en) 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
GB9910975D0 (en) * 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
US6566329B1 (en) * 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US6102896A (en) * 1999-09-08 2000-08-15 Cambridge Biostability Limited Disposable injector device
US7651703B2 (en) * 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
AU2001233180A1 (en) * 2000-02-10 2001-08-20 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
CA2406790C (fr) 2000-04-19 2009-07-07 Genentech, Inc. Formulations a liberation lente
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001085136A2 (fr) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Poudres a base de phospholipides permettant de distribuer un medicament
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6653062B1 (en) * 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
JP2004515467A (ja) 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
ATE450253T1 (de) * 2000-10-13 2009-12-15 Cambridge Biostability Ltd Pharmazeutische flüssige suspensionen
ATE420630T1 (de) * 2000-11-29 2009-01-15 Itoham Foods Inc Pulverzubereitungen und verfahren zu ihrer herstellung
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
AU2002242231B2 (en) * 2001-02-23 2007-09-06 Genentech, Inc. Erodible polymers for injection
ES2554106T3 (es) * 2001-06-21 2015-12-16 Genentech, Inc. Formulación de liberación sostenida
GB0116074D0 (en) * 2001-06-29 2001-08-22 Univ Strathclyde Nanoparticle structures
US7615234B2 (en) * 2001-09-11 2009-11-10 Glide Pharmaceutical Technologies Limited Drug delivery technology
GB2379390B (en) * 2001-09-11 2005-01-26 Caretek Medical Ltd A novel drug delivery technology
MXPA04005865A (es) 2001-12-19 2004-09-13 Nektar Therapeutics Suministro de aminoglucosidos a los pulmones.
AU2003221808A1 (en) * 2002-04-05 2003-10-27 Powerzyme, Inc. Analyte sensor
KR100508911B1 (ko) * 2002-05-09 2005-08-18 주식회사 펩트론 서방성 단백질 약물 제형 및 이의 제조방법
GB2421689B (en) 2002-08-05 2007-03-07 Caretek Medical Ltd Drug delivery system
CN100444848C (zh) * 2002-09-27 2008-12-24 特里梅里斯公司 HIV gp41-衍生肽的改善用药的药物组合物
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
AU2003286472A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
ZA200505306B (en) * 2002-12-31 2006-09-27 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers
KR20050090430A (ko) * 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
US20040197413A1 (en) * 2003-04-04 2004-10-07 Genteric, Inc. Spray dry coacervation systems and methods
DE10320609A1 (de) * 2003-05-08 2004-12-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Sprühgefriergranulate mit verbesserter Homogenität der Eigenschaftsverteilung und Verfahren zu deren Herstellung
US7090433B2 (en) * 2003-10-07 2006-08-15 Steve Searby Underground cable laying apparatus
US20050095320A1 (en) * 2003-10-29 2005-05-05 Richard Botteri [An Isotonic Sports Drink for Female Athletes Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Nutrition During Execise and Competition]
US20050100636A1 (en) * 2003-11-10 2005-05-12 Megan Botteri [A Low-Calorie Sports Drink For Physically Active Women That is Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Replacing Electrolytes Lost During Periods of Physical Activity]
RU2006128593A (ru) * 2004-01-07 2008-02-20 Тримерис, Инк. (Us) Синтетические пептиды, производные области hr2 белка gp41 вич, и их применение в терапии для ингибирования проникновения вируса иммунодефицита человека
ATE531374T1 (de) 2004-04-15 2011-11-15 Alkermes Inc Vorrichtung auf polymerbasis mit verzögerter freisetzung
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
US7133638B2 (en) * 2004-11-18 2006-11-07 Xerox Corporation Scanning method and an image-processing device including the same
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
GB2422784A (en) * 2005-02-07 2006-08-09 Caretek Medical Ltd Disposable assembly comprising a needle or stylet
AR053026A1 (es) * 2005-03-08 2007-04-18 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
CN100337684C (zh) * 2005-05-11 2007-09-19 北京双鹭药业股份有限公司 一种胸腺五肽的水溶液制剂、其制备方法及应用
CN100342909C (zh) * 2005-05-11 2007-10-17 北京双鹭药业股份有限公司 一种胸腺素α1的水溶液制剂、其制备方法及应用
CN100336557C (zh) * 2005-05-11 2007-09-12 北京双鹭药业股份有限公司 一种生长抑素的水溶液制剂、其制备方法及应用
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
ES2436616T5 (es) * 2005-12-20 2022-05-27 Bristol Myers Squibb Co Formulaciones proteicas estables
US9309316B2 (en) * 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US20090023629A1 (en) * 2005-12-23 2009-01-22 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
NZ570300A (en) 2006-02-02 2011-08-26 Trimeris Inc HIV fusion inhibitor peptides with improved biological properties
US9156950B2 (en) * 2006-03-13 2015-10-13 Naturin Gmbh & Co. Collagen powder and collagen-based thermoplastic composition for preparing conformed articles
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
WO2008118133A2 (fr) 2006-09-26 2008-10-02 Trustees Of Tufts College Microsphères de soie pour l'encapsulation et la libération contrôlée
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
AU2007333959A1 (en) * 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
ATE516814T1 (de) * 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
EP2139526A4 (fr) * 2007-04-03 2010-07-14 Trimeris Inc Nouvelles formulations destinées à l'application de thérapies peptidiques antivirales
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
EP2164458A1 (fr) * 2007-06-01 2010-03-24 Novo Nordisk A/S Compositions pharmaceutiques non aqueuses stables
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
EP2187932B1 (fr) 2007-08-07 2015-01-28 DePuy Synthes Products, LLC Formules protéiniques comprenant le facteur gdf-5 dans une solution aqueuse acide
KR20100080812A (ko) * 2007-09-25 2010-07-12 트라이머리스, 인코퍼레이티드 치료용 항-ｈｉｖ 펩티드의 합성 방법
EP2240155B1 (fr) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Dispositifs, formulations et méthodes d administration de plusieurs agents bénéfiques
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
WO2009115469A1 (fr) 2008-03-18 2009-09-24 Novo Nordisk A/S Analogues de l'insuline acylés stabilisés vis-à-vis des protéases
CN102026619A (zh) * 2008-04-14 2011-04-20 先进科技及再生医学有限责任公司 液体缓冲的gdf-5制剂
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
UA106606C2 (uk) * 2009-03-16 2014-09-25 Родія Оперейшнс Стабілізована біоцидна композиція
US20120070427A1 (en) 2009-06-01 2012-03-22 Trustees Of Tufts College Vortex-induced silk fibroin gelation for encapsulation and delivery
RU2431496C2 (ru) * 2009-09-15 2011-10-20 Общество С Ограниченной Ответственностью "Герофарм" Инъекционная лекарственная форма для лечения острого ишемического инсульта и черепно-мозговой травмы, способ ее изготовления и применение
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
EP2542257B1 (fr) 2010-03-01 2017-07-05 Bayer Healthcare LLC Optimisation d'anticorps monoclonaux dirigés contre l'inhibiteur de la voie du facteur tissulaire (tfpi)
WO2011109691A2 (fr) 2010-03-05 2011-09-09 Trustees Of Tufts College Compositions ionomères à base de soie
GB201004072D0 (en) 2010-03-11 2010-04-28 Turzi Antoine Process, tube and device for the preparation of wound healant composition
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR102196009B1 (ko) 2011-10-25 2021-01-04 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
WO2013096835A1 (fr) * 2011-12-23 2013-06-27 Abbvie Inc. Formulations stables de protéine
JP6195848B2 (ja) 2012-01-27 2017-09-13 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 糖ポリマーを用いた生体分子の安定化
CA2870313A1 (fr) 2012-04-11 2013-10-17 Novo Nordisk A/S Formulations a base d'insuline
WO2014035798A1 (fr) 2012-08-30 2014-03-06 Sanofi Lyogels de soie pour la libération prolongée de produits thérapeutiques protéiques et procédés de fabrication et d'utilisation associés
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
SG10201809228RA (en) * 2014-04-28 2018-11-29 Eisai R&D Man Co Ltd Lyophilized formulation of hgf
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
WO2017104759A1 (fr) * 2015-12-16 2017-06-22 株式会社 資生堂 Produit cosmétique lyophilisé du type comprimé
MX2018010283A (es) 2016-03-17 2019-01-31 Eisai R&D Man Co Ltd Metodo para producir factor de crecimiento de hepatocitos (hgf) activo.
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3484450A4 (fr) * 2016-07-18 2020-04-01 Tissuegen, Inc. Procédés et compositions pour maintenir la conformation et l'intégrité structurale de biomolécules
HRP20221324T1 (hr) 2016-12-16 2022-12-23 Novo Nordisk A/S Farmaceutski pripravci koji sadrže inzulin
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
JP6404405B1 (ja) * 2017-06-14 2018-10-10 株式会社 資生堂 タブレット型凍結乾燥化粧料
CN110769810B (zh) * 2017-06-19 2023-08-01 株式会社资生堂 片剂型冷冻干燥化妆品
TWI787186B (zh) * 2017-06-19 2022-12-21 日商資生堂股份有限公司 錠型凍結乾燥化妝料
CN108169499A (zh) * 2017-11-30 2018-06-15 成都斯马特科技有限公司 一种基于生化试剂盘进行凝血分析的方法
KR102664288B1 (ko) * 2018-09-14 2024-05-09 케러 테라퓨틱스, 인코포레이티드 카파 오피오이드 수용체 효능제의 경구 제형
WO2020154305A1 (fr) 2019-01-21 2020-07-30 Eclipse Medcorp, Llc Procédé, système et appareil pour séparer des composants d'un échantillon biologique
AU2020372939A1 (en) 2019-10-31 2022-06-09 Crown Laboratories, Inc. Systems, methods and apparatus for separating components of a sample
AU2023215312A1 (en) * 2022-02-01 2024-07-25 Ocular Therapeutix, Inc. A controlled release implant for biologics and corresponding methods of treatment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3664963A (en) * 1969-10-22 1972-05-23 Balchem Corp Encapsulation process
IT1103817B (it) * 1978-06-27 1985-10-14 Guaber Spa Composizione deodorante granulare per posacenere
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0193917A3 (fr) * 1985-03-06 1987-09-23 American Cyanamid Company Compositions dispersibles et solubles dans l'eau de polymères pour administration parentérale
US4891319A (en) * 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JP2526589B2 (ja) * 1986-08-08 1996-08-21 武田薬品工業株式会社 ペプチド含有マイクロカプセルおよびその製造法
US5312745A (en) * 1987-06-18 1994-05-17 Chromogenix Ab Determination of components active in proteolysis
DE3782737T3 (de) * 1987-08-21 1999-05-20 Imcera Group Inc., Northbrook, Ill. Stabilisierung von Wachstumshormonen.
WO1989003671A1 (fr) * 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Preparation a liberation entretenue
GB8801338D0 (en) * 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
AT392079B (de) * 1988-03-11 1991-01-25 Voest Alpine Ind Anlagen Verfahren zum druckvergasen von kohle fuer den betrieb eines kraftwerkes
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5039540A (en) * 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5312705A (en) * 1990-07-27 1994-05-17 Matsushita Electric Industrial Co., Ltd. Photosensitive materials for electrophotography having a double-layer structure of a charge generation layer and a charge transport layer
AU1442592A (en) * 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
FR2673843B1 (fr) * 1991-03-14 1995-01-13 Centre Nat Rech Scient Composition pharmaceutique implantable, bioresorbable a base de poly(acide lactique), destinee a mettre en óoeuvre une antibiotherapie interne locale.
ATE223702T1 (de) * 1993-10-22 2002-09-15 Genentech Inc Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
DK0724432T3 (da) * 1993-10-22 2003-01-27 Genentech Inc Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner
EP0724433B1 (fr) * 1993-10-22 1998-12-30 Genentech, Inc. Procede de preparation de microspheres avec etape de sechage en lit fluidise

Also Published As

Publication number Publication date
AU6241294A (en) 1994-09-14
AU685784B2 (en) 1998-01-29
JPH08507064A (ja) 1996-07-30
EP0686045B1 (fr) 2000-11-15
DK0686045T3 (da) 2001-03-05
RU2143889C1 (ru) 2000-01-10
US5589167A (en) 1996-12-31
CZ296649B6 (cs) 2006-05-17
ATE197550T1 (de) 2000-12-15
IL108713A0 (en) 1994-05-30
US5753219A (en) 1998-05-19
PT686045E (pt) 2001-04-30
EP0686045A1 (fr) 1995-12-13
WO1994019020A1 (fr) 1994-09-01
DE69426292D1 (de) 2000-12-21
IL108713A (en) 1999-12-22
CZ212795A3 (en) 1996-02-14
CN1118143A (zh) 1996-03-06
GR3035383T3 (en) 2001-05-31
DE69426292T2 (de) 2001-05-17
JP3698721B2 (ja) 2005-09-21
CN1108823C (zh) 2003-05-21
NZ262634A (en) 1997-02-24
US5804557A (en) 1998-09-08
ES2153418T3 (es) 2001-03-01

Similar Documents

Publication Publication Date Title
ZA941239B (en) Excipient stabilazation of polypeptides treated with organic solvents
EP0741188A3 (fr) Insuline monocaténaire avec bioactivité élevée
CA2158937A1 (fr) Vecteurs d'alphavirus recombinant
HK1022701A1 (en) Exendin analogues, processes for their preparationand medicaments containing them exendin.
NZ260989A (en) Xylanase derived from bacillus pumilus prl b12 or from b.licheniformis and mutants and variants thereof
GR3024872T3 (en) Non-abrasive mechanical fastening system and process of manufactue therefor.
ZA922476B (en) Multifunctional water-dispersible crossliking agents
MY116146A (en) Stabilizer combination
AU1470292A (en) Stabilized factor viii preparations
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
TW349953B (en) Carrot antifreeze polypeptides
FI941776A (fi) Menetelmä 1,2,4-tiadiatsolien valmistamiseksi
EP0643133A3 (fr) D-hydantoinase récombinante, procédé de sa préparation et son utilisation.
EP0628591A3 (fr) Polyorganosiloxanes ayant des substituants 1,3,5-triazine.
ZA943904B (en) Heterocyclic chemistry
WO1995026739A3 (fr) Utilisation de dextrane substitue pour le traitement des lesions du systeme nerveux et fractions enrichies en herapane sulfate
CA2154164A1 (fr) Stabilisation d'excipients de polypeptides traites par des solvants organiques
EP0661401A3 (fr) Agent de traitement de matériaux textiles.
NO981707L (no) Xylanase, oligonukleotidsekvens som koder for xylanase og anvendelse derav
HK1047958A1 (en) Novel polypeptides and genes encoding the same
MY107451A (en) Cloning and expression of a rhoptry associated protein of p.falciparum
GR3033151T3 (en) Vaccine protecting against porcine hemophilus.
HUT69324A (en) Protection group, process and apparatus for using the protection group
DE60014655D1 (en) Polypeptide
Lunarska HYDROGEN INDUCED DEGRADATION OF INDUSTRIAL INSTALLATION, ITS MONITORING AND PREVENTING(Polish)